Leaflet: information for the user
Pregabalin cinfa 200 mg hard capsules EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Pregabalina cinfa belongs to a group of medications used for the treatment of epilepsy, peripheral and central neuropathic pain, and generalized anxiety disorder (GAD) in adults.
Peripheral and central neuropathic pain:Pregabalina is used for the treatment of chronic pain caused by nerve damage. Various diseases can cause peripheral neuropathic pain, such as diabetes or herpes. The sensation of pain could be described as heat, burning, pulsating pain, stabbing pain, acute pain, spasms, continuous pain, numbness, tingling, and pins and needles sensation. Peripheral and central neuropathic pain could also be associated with mood changes, sleep disturbances, fatigue (tiredness), and may affect physical and social activity and overall quality of life.
Epilepsy:Pregabalina is used in the treatment of certain types of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe this medication to treat epilepsy when your current treatment does not control the disease. You must take pregabalina in addition to your current treatment. This medication should not be administered alone, but always used in combination with other antiepileptic treatments.
Generalized anxiety disorder:Pregabalina is used in the treatment of generalized anxiety disorder (GAD). Symptoms of GAD include excessive and prolonged anxiety and worry that are difficult to control. GAD can also produce restlessness or feeling of excitement or nervousness, feeling easily fatigued (tired), difficulty concentrating or feeling mentally blank, irritability, muscle tension, or sleep disturbances. This is different from the stress and tensions of everyday life.
If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine
Dependence
Some people may become dependent on pregabalin (need to continue taking the medicine). They may experience withdrawal effects when they stop using pregabalin (see section 3, "How to take Pregabalina cinfa" and "If you interrupt treatment with Pregabalina cinfa"). If you are concerned that you may become dependent on pregabalin, it is essential that you consult your doctor.
If you notice any of the following signs while taking pregabalin, it could be a sign that you have become dependent:
If you notice any of these signs, talk to your doctor to analyze the best care plan for you, including when it is appropriate to stop treatment and how to do it safely.
Children and adolescents
The safety and efficacy have not been established in children and adolescents (under 18 years) so pregabalin should not be used in this age group.
Other medicines and Pregabalina cinfa with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Pregabalin and certain medicines may exert a mutual influence between them (interactions). When this medicine is used with certain medicines that have a sedative effect (including opioids), those effects may be potentiated, and it may lead to respiratory failure, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken with other medicines that contain:
This medicine can be taken with oral contraceptives.
Taking Pregabalina cinfa with food, drinks, and alcohol
Pregabalin capsules can be taken with and without food.
It is recommended not to take alcohol during treatment with this medicine.
Pregnancy and breastfeeding
You should not take pregabalin during pregnancy or lactation, unless your doctor has told you to. The use of pregabalin during the first 3 months of pregnancy may cause congenital anomalies in the fetus that require medical treatment. In a study that reviewed data from women in Nordic countries who took pregabalin during the first 3 months of pregnancy, 6 babies out of 100 had such congenital anomalies. This contrasts with 4 babies out of 100 born to women not treated with pregabalin in the study. Congenital anomalies of the face (cleft palate), eyes, nervous system (including the brain), kidneys, and genitals have been reported.
A reliable contraceptive method should be used in women of childbearing age. If you are pregnant or breastfeeding, believe you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and operating machinery
Pregabalin may cause dizziness, somnolence, and decreased concentration. You should not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medicine affects your ability to perform these activities.
Pregabalina cinfa contains lactose
If your doctor has told you that you have a lactose intolerance, consult with him before taking this medicine.
Your doctor will determine the appropriate dose for you.
This medication is exclusively for oral use.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:
If you estimate that the action of this medication is too strong or too weak, inform your doctor or pharmacist.
If you are an elderly patient (over 65 years old), you should take pregabalin normally, except if you have kidney problems.
Your doctor may prescribe a different dosing regimen or dose if you have kidney problems.
Swallow the capsule whole with water.
Continue taking this medication until your doctor tells you to stop.
If you take more Pregabalina cinfa than you should
Call your doctor or go to the nearest emergency service immediately. Bring the box or bottle of pregabalin capsules with you. As a result of taking too much pregabalin, you may feel drowsy, confused, agitated, or restless. Seizures and loss of consciousness (coma) have also been reported.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Pregabalina cinfa
It is essential to take the pregabalin capsules regularly at the same time every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose normally. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Pregabalina cinfa
Do not stop taking this medication suddenly. If you want to stop taking pregabalin, talk to your doctor first. He will tell you how to do it. If you are going to stop treatment, this should be done gradually over a minimum of one week.
Once a short- or long-term treatment with pregabalin is completed, you should know that you may experience certain adverse effects, called withdrawal effects. These effects include sleep problems, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, sweating, and dizziness. These effects may appear more frequently or severely if you have been taking this medication for a longer period. If you experience withdrawal effects, consult your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known: cannot be estimated from available data
Once a short- or long-term treatment with pregabalin is completed, you should know that you may experience certain side effects, called withdrawal effects (see "If you stop taking Pregabalin cinfa").
If you experience swelling in the face or tongue, or if your skin becomes red and blisters or peels, you should seek immediate medical attention.
Certain side effects, such as drowsiness, may be more frequent since patients with spinal cord injury may be taking other medications to treat, for example, pain or spasticity (tense or rigid muscles), with side effects similar to those of pregabalin, so the intensity of these side effects may increase when taken together.
The following adverse reaction has been reported in post-marketing experience: difficulty breathing, shallow breathing.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es/www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the packaging or in the bottle after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medicines at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medicines. By doing so, you will help protect the environment.
Each hard capsule contains 200 mg of pregabalin.
Hard capsule content:lactose monohydrate, cornstarch and talc.
Capsule coating:gelatin, titanium dioxide (E-171) and iron oxide red (E-172).
Product appearance and packaging contents
Hard gelatin capsules with a pink-orange body with the logo “200 mg” and a pink-orange cap with the logo “A002”.
Pregabalina cinfa 200 mg is presented in PVC-PVDC/Aluminum blister packaging containing 84 hard capsules.
Marketing authorization holder and responsible manufacturer
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Areta Industrial Estate
31620 Huarte (Navarra) - Spain
Last review date of this leaflet:May 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medication by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/85277/P_85277.html
QR code link to:https://cima.aemps.es/cima/dochtml/p/85277/P_85277.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.